Beat CF logo
  • Home
  • Our Team
  • BEAT CF
    • FAQ
    • About Adaptive Clinical Trials
  • News & Events
  • Contact Us
Characteristics, treatment, and lung function outcomes of pulmonary exacerbations in cystic fibrosis: insights from the BEAT-CF cohort

Characteristics, treatment, and lung function outcomes of pulmonary exacerbations in cystic fibrosis: insights from the BEAT-CF cohort

by Danielle Miller | Nov 26, 2025 | Category 1

This study examined serious lung infections, known as pulmonary exacerbations, in people with cystic fibrosis (CF) who needed treatment with intravenous (IV) antibiotics. These severe flare-ups are important because they can cause lasting drops in lung function and...

Recent Posts

  • Characteristics, treatment, and lung function outcomes of pulmonary exacerbations in cystic fibrosis: insights from the BEAT-CF cohort
  • The BEAT CF trial was used in research looking at meaningful outcomes of clinical trials
  • A description of characteristics of the participants who enrolled in the prospective BEAT CF cohort
  • Survey to find out what matters most to people with CF
  • Ethics & governance approved at PCH for BEAT CF platform

Archives

  • November 2025
  • August 2025
  • July 2025
  • September 2020
  • November 2019

Categories

  • Category 1

BEAT CF

We are a team aiming to optimise the medical management of cystic fibrosis lung exacerbations.

Quick links

> Our team
> BEAT CF
> News & events
> FAQ’s
> Privacy policy

Contact us

Email
info@beatcf.org.au



Join us on Twitter



Join us on Twitter

Contact us

We are located at:

Telethon Kids Institute
Northern Entrance, Perth Children’s Hospital
15 Hospital Ave,
Nedlands WA 6009

Quick links

> Our team
> BEAT CF
> Participants
> Register your interest
> News & events
> FAQ’s
> Privacy policy

ThereĀ 

Quick links

> Our team
> BEAT CF
> Participants
> Register your interest
> News & events
> FAQ’s
> Privacy policy

BEAT CF

We are a network of Australian researchers, clinicians, allied health professionals and community members aiming to optimise the medical management of cystic fibrosis lung exacerbations (infections).